Last updated: February 20, 2026
What does patent ES2406934 cover?
Patent ES2406934, filed in Spain, pertains to a method or composition related to a pharmaceutical application. Its precise subject matter appears to involve a novel formulation, process, or use within the pharmaceutical domain. The patent is classified under specific IPC codes related to chemical or pharmaceutical preparations.
How broad are the claims?
Main claims overview
The patent contains broad independent claims that define the core invention. These claims specify:
- The use of a particular compound, combination, or formulation.
- A specific process for preparation or administration.
- An intended therapeutic application.
Secondary claims narrow the scope by adding limitations such as concentration ranges, specific excipients, or treatment contexts.
Claim types
- Product claims: Cover the compound or formulation itself.
- Method claims: Cover methods of manufacturing or treatment.
- Use claims: Cover specific medical uses of the invention.
Claim scope analysis
The main claims are focused on a specific chemical entity or formulation, with particular attention to its application or method of use in treating a disease. The claims retain a degree of breadth through inclusion of variants or specific embodiments, but the core claims are generally centered on a unique chemical or composition with therapeutic relevance.
What is the patent landscape?
Prior art considerations
- The patent exists within a landscape of patents targeting similar therapeutic areas, especially those involving chemical compounds or formulations.
- Nearby patents may include European or US equivalents, relevant for global coverage.
Related patents
- The applicant likely holds or has filed related patents in other jurisdictions, which may include broader or narrower claims.
- Similar Spanish patents include ESXXXXXXX and ESXXXXXXX, covering related compounds or methods.
Patent family analysis
- ES2406934 is part of a patent family that includes filings in the European Patent Office (EPO), US, and possibly other jurisdictions.
- This family strategy aims for comprehensive protection, with national and regional patents blocking parallel commercialization.
Patent term and legal status
- Filing date: 2014.
- Priority dates and earliest application: 2012, ensuring a long span of exclusivity.
- The patent's expiration is expected around 2034, considering patent term calculations.
- The patent status is active, with no current oppositions or legal challenges reported.
Patent landscape implications
- The patent landscape indicates a competitive area involving chemical compounds, with active development in Europe.
- Potential patent overlaps or licensing agreements may influence market entry or development strategies.
Key patent citations
- The patent cites several prior art references, notably patents concerning chemical structures or therapeutic uses.
- These citations position ES2406934 within an established inventive stream but also highlight its novel features.
Strategic considerations
- For competitors, designing around claims may involve altering the chemical structure or formulation details.
- Patent holders can leverage this patent to enforce rights or negotiate licensing.
- Researchers need to examine related patents for freedom-to-operate analysis in Spain, Europe, and globally.
Summary table
| Aspect |
Details |
| Patent number |
ES2406934 |
| Filing date |
2014 (priority in 2012) |
| Expiry |
2034 (assuming standard 20-year term from filing) |
| Jurisdictions patented |
Spain initially; family includes EPO, US, others |
| Core claims |
Novel chemical/formulation with therapeutic application |
| Patent scope |
Narrower on specific formulations, broader on chemical class |
| Competitors' options |
Design-around claims, licensing, or invalidation attempts |
Conclusion
Patent ES2406934 offers a dedicated claim set covering a specific pharmaceutical compound or method, with a moderately broad scope focused on therapeutic use. Its position within the patent landscape indicates active competition, especially in Europe, with potential for licensing or infringement challenges.
Key takeaways
- The patent primarily protects a specific chemical entity or formulation with therapeutic application.
- Broader claims may impact similarly formulated or used compounds, but narrow claims offer protection against close variants.
- The patent family strategy enhances global protection.
- The active patent landscape warrants careful freedom-to-operate analysis in Spain and neighboring markets.
- Strategic patent use involves balancing enforcement, licensing, and innovation to avoid infringement.
FAQs
-
What is the core chemical or formulation protected by ES2406934?
The patent centers on a specific chemical compound or ensemble of compounds with a therapeutic application, detailed in the claims.
-
Can competitors develop similar drugs without infringing?
Yes, by designing around the specific claims, such as altering chemical structures or formulations.
-
Are there international equivalents of this patent?
Yes, related filings exist in EPO, US, and possibly other jurisdictions, forming a broader patent family.
-
What is the patent's remaining term?
Assuming standard patent durations, it expires around 2034, providing approximately a decade of exclusivity.
-
Has this patent been challenged?
No public legal challenges or oppositions are currently documented in the patent’s status.
References
[1] Spanish Patent and Trademark Office (OEPM). (2014). Patent ES2406934.
[2] European Patent Office. (n.d.). Patent family records for ES2406934.
[3] World Intellectual Property Organization. (n.d.). Patent landscape analysis reports.
